KCT0002005已完成未知
A dose block-randomized, double blinded, placebo controlled, dose-escalation clinical trial to evaluate the safety, tolerability and pharmacokinetics after single oral doses of AVI-CO-004 in healthy male subject
Avixgen0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 20(Year) 至 45(Year)（—）
- 性别
- Male
入选标准
- •1)Adult male of age 20~45, at the screening.
- •2)Individual having weight within ideal body weight ±20% and over 55kg.
- •- Ideal body weight = (Height cm - 100) X 0.9
- •3)Individual certainly consented to not donate sperms to 3 months after finishing of test and to use contraception during clinical test.
- •4)Individual consented by letter to determine involvement by themselves and to follow requirement after listening minutely about this clinical study
排除标准
- •1)Individual with clinically significant and active cardiovascular diseases, respiratory diseases, renal diseases, endocrine disorders, hematologic diseases, digestive disorders, central nervous system disorders, mental illness or malignant tumor or Individual having any history of aforementioned diseases.
- •2)Individual having gastrointestinal diseases that can affect the absorption of drugs (Crohn’s disease, ulcers, acute or chronic pancreatitis, etc.) or having a history of gastrointestinal surgery (however, simple appendectomy or hernia surgery are excluded).
- •3)Individual who has hypersensitivity or has history of clinically significant hypersensitivity reactions to the active ingredient.
- •4)Individual who considered unsuitable through health examination that are performed during screening (Disease history, physical examination, vital signs, ECG, laboratory tests, etc.)
- •5)Individual who has laboratory test results showing the numbers of those below
- •- Hemoglobin < 13.0 g/dL
- •- Serum AST or ALT > 1.25 times the normal limit.
- •- Serum total bilirubin > 1.25 times the normal limit.
- •- Serum Creatin phosphokinase(CPK) > 1.25 times the normal limit.
- •-In case of eGFR (estimated Glomerular Filtration Rate) <60 mL / min / 1.73m2 using the MDRD (Modification of Diet in Renal Disease) formula
- •6)After achieving stability more than 5 minutes in a sitting posture, Individual showing vital sign readings for the systolic blood pressure = 150 mmHg or =100mmHg, for diastolic blood pressure = 100 mmHg or = 65 mmHg.
- •7)12-lead ECG examination result showing that QTcB interval is more than 450ms.
- •8)Individual having history of drug abuse or showing positive results for drugs abuse in drug screening tests.
- •9)Individual who has taken excessive of caffeine, alcohol or cigarette ( Caffeine :> 5 cups / day, Alcohol :> 210g / week, Cigarette: > 10 cigarettes / day).
- •10)Individual who has taken test drugs from other clinical tests within 90 days prior to test drug administration.
- •11)Individual who has taken the drugs that induce and suppress drug-metabolizing enzymes, such as barbiturates, within 30 days prior to test drug administration.
- •12)Individual who has done whole blood donation within 60 days or Individual who has done apheresis blood donation within 30 days prior to the test drug administration.
- •13)Individual who has done whole blood donation within 60 days or Individual who has done apheresis blood donation within 30 days prior to the test drug administration.
- •14)Individual who has taken preion drug, Korean traditional medicine, or vitamin pills within 14 days before test drug administration.
- •15)Individual who considered unsuitable by investigators due to other reasons.
研究者
相似试验
尚未招募
不适用
Phase I clinical trial to investigate the safety, tolerability and pharmacokinetics of A4368 in healthy subjectsKCT0006346Autophagy Sciences78
招募中
不适用
Dose-escalation clinical trial to find the maximum tolerable dose after single oral dose of HL237KCT0002539The Catholic University of Korea, Seoul St. Mary's Hospital56
招募中
不适用
Clinical trial to evaluate the safety, tolerability and pharmacokinetics after multiple oral doses of AVI-CO-004KCT0002279Avixgen18
已完成
不适用
Phase 1 study for NASHKCT0005295J2H Biotech100
招募中
不适用
A dose block-randomized, double-blind, placebo-controlled, single/multiple dosing, dose-escalation clinical phase 1 trial to investigate the safety, tolerability, and pharmacokinetics of DWP09031 after oral administration in healthy male subjectsKCT0000343Inje University Busan Paik Hospital64